. . "005.001" . . . "Intenz\u00EDvn\u011B p\u016Fsob\u00EDc\u00ED anxiolytikum se sedativn\u00EDm, antikonvulzivn\u00EDm a myorelaxa\u010Dn\u00EDm \u00FA\u010Dinkem, ur\u010Den\u00E9 p\u0159edev\u0161\u00EDm na kr\u00E1tkodobou l\u00E9\u010Dbu akutn\u00EDch stav\u016F. Terapeutick\u00FD \u00FA\u010Dinek se zakl\u00E1d\u00E1 na ovlivn\u011Bn\u00ED limbick\u00E9ho syst\u00E9mu, thalamu a hypothalamu. \nNem\u00E1 v\u00FDrazn\u00FD vliv na perifern\u00ED vegetativn\u00ED syst\u00E9m, nevyvol\u00E1v\u00E1 extrapyramid\u00E1ln\u00ED syndrom. Diazepam jako jin\u00E9 benzodiazepiny zvy\u0161uje pr\u00E1h pro vznik k\u0159e\u010D\u00ED. \nDiazepam se v\u00E1\u017Ee na specifick\u00E9 benzodiazepinov\u00E9 receptory v\u00A0r\u016Fzn\u00FDch oblastech mozku a potencuje inhibi\u010Dn\u00ED \u00FA\u010Dinky kyseliny gamaaminom\u00E1seln\u00E9 (GABA) na chloridov\u00FD kan\u00E1l, \u010D\u00EDm zvy\u0161uje inhibici synaptick\u00E9 transmise zprost\u0159edkovanou p\u0159es GABA. \n"@cs . "5.1. Farmakodynamick\u00E9 vlastnosti "@cs .